Hepatitis C treatment is no longer prohibitively expensive in the Global South because Malaysia, Thailand, Egypt and the Drugs for Neglected Diseases initiative developed ravidasvir – a low-cost antiviral. Such breakthroughs are possible for other neglected diseases if low- and middle-income countries agree to act collectively.